Print

Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

https://www.facingourrisk.org/research-clinical-trials/study/279/treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u


Treatment for ER-positive, HER2-negative metastatic breast cancer

About the Study

NOTE - This study is no longer recruiting patients. 

 

Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance).

 

This Study is Open To:

NOTE - This study is no longer recruiting patients. 

This Study is Not Open To:

NOTE - This study is no longer recruiting patients. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.